KR20190053250A - Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법 - Google Patents

Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법 Download PDF

Info

Publication number
KR20190053250A
KR20190053250A KR1020197011455A KR20197011455A KR20190053250A KR 20190053250 A KR20190053250 A KR 20190053250A KR 1020197011455 A KR1020197011455 A KR 1020197011455A KR 20197011455 A KR20197011455 A KR 20197011455A KR 20190053250 A KR20190053250 A KR 20190053250A
Authority
KR
South Korea
Prior art keywords
inhibitor
patient
dose
severe
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197011455A
Other languages
English (en)
Korean (ko)
Inventor
알렌 라딘
닐 그라함
볼라늘 아킨레이드
기안루카 피로치
싱 쑨
토마스 훌트쉬
브래드 에스. 슈멜
아시쉬 반살
Original Assignee
리제너론 파아마슈티컬스, 인크.
사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59974890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190053250(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파아마슈티컬스, 인크., 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 filed Critical 리제너론 파아마슈티컬스, 인크.
Priority to KR1020227045686A priority Critical patent/KR20230006049A/ko
Priority claimed from PCT/US2017/052772 external-priority patent/WO2018057776A1/en
Publication of KR20190053250A publication Critical patent/KR20190053250A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197011455A 2016-09-22 2017-09-21 Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법 Ceased KR20190053250A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227045686A KR20230006049A (ko) 2016-09-22 2017-09-21 Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662397988P 2016-09-22 2016-09-22
US62/397,988 2016-09-22
US201762442083P 2017-01-04 2017-01-04
US62/442,083 2017-01-04
US201762443819P 2017-01-09 2017-01-09
US62/443,819 2017-01-09
US201762445774P 2017-01-13 2017-01-13
US62/445,774 2017-01-13
US201762519896P 2017-06-15 2017-06-15
US62/519,896 2017-06-15
EP17306081.5 2017-08-18
EP17306081 2017-08-18
PCT/US2017/052772 WO2018057776A1 (en) 2016-09-22 2017-09-21 Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045686A Division KR20230006049A (ko) 2016-09-22 2017-09-21 Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법

Publications (1)

Publication Number Publication Date
KR20190053250A true KR20190053250A (ko) 2019-05-17

Family

ID=59974890

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197011455A Ceased KR20190053250A (ko) 2016-09-22 2017-09-21 Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
KR1020247032347A Pending KR20240146104A (ko) 2016-09-22 2017-09-21 Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
KR1020227045686A Ceased KR20230006049A (ko) 2016-09-22 2017-09-21 Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247032347A Pending KR20240146104A (ko) 2016-09-22 2017-09-21 Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
KR1020227045686A Ceased KR20230006049A (ko) 2016-09-22 2017-09-21 Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법

Country Status (13)

Country Link
US (1) US20220110999A1 (cg-RX-API-DMAC7.html)
EP (2) EP3515465B1 (cg-RX-API-DMAC7.html)
JP (3) JP7164530B2 (cg-RX-API-DMAC7.html)
KR (3) KR20190053250A (cg-RX-API-DMAC7.html)
CN (2) CN118203659A (cg-RX-API-DMAC7.html)
AU (2) AU2017332732B2 (cg-RX-API-DMAC7.html)
CA (1) CA3037499A1 (cg-RX-API-DMAC7.html)
ES (1) ES2974376T3 (cg-RX-API-DMAC7.html)
HU (1) HUE066662T2 (cg-RX-API-DMAC7.html)
IL (2) IL310371A (cg-RX-API-DMAC7.html)
MX (3) MX2019003235A (cg-RX-API-DMAC7.html)
PL (1) PL3515465T3 (cg-RX-API-DMAC7.html)
RU (1) RU2759630C2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN118286417A (zh) 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
PT3110848T (pt) 2014-09-24 2024-03-05 Regeneron Pharma Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
KR102872485B1 (ko) 2016-09-01 2025-10-20 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
CN111494626B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
JP7736667B2 (ja) 2019-08-05 2025-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
KR20230084166A (ko) * 2020-10-09 2023-06-12 쿄와 기린 가부시키가이샤 Ox40 관련 질환을 치료하는 방법
EP4277929A1 (en) * 2021-01-14 2023-11-22 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
WO2002055101A2 (en) * 2000-12-21 2002-07-18 Inhale Therapeutic Syst Storage stable powder compositions of interleukin-4 receptor
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
CN118286417A (zh) * 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
TWI634900B (zh) * 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r

Also Published As

Publication number Publication date
MX2024011262A (es) 2024-09-23
MX2019003235A (es) 2019-07-08
JP2019529560A (ja) 2019-10-17
CN118203659A (zh) 2024-06-18
JP2024174962A (ja) 2024-12-17
AU2017332732A1 (en) 2019-04-11
RU2019111921A (ru) 2020-10-22
PL3515465T3 (pl) 2024-08-12
RU2759630C2 (ru) 2021-11-16
EP3515465A1 (en) 2019-07-31
AU2024203951A1 (en) 2024-07-04
IL265516A (en) 2019-05-30
CN109963577A (zh) 2019-07-02
RU2019111921A3 (cg-RX-API-DMAC7.html) 2020-12-29
HUE066662T2 (hu) 2024-09-28
CA3037499A1 (en) 2018-03-29
KR20230006049A (ko) 2023-01-10
JP7164530B2 (ja) 2022-11-01
EP4345110A3 (en) 2024-06-12
IL265516B2 (en) 2024-06-01
IL310371A (en) 2024-03-01
KR20240146104A (ko) 2024-10-07
IL265516B1 (en) 2024-02-01
AU2017332732B2 (en) 2024-03-14
EP3515465B1 (en) 2024-02-07
MX2023014187A (es) 2024-01-16
CN109963577B (zh) 2024-03-12
US20220110999A1 (en) 2022-04-14
JP2022160685A (ja) 2022-10-19
EP4345110A2 (en) 2024-04-03
ES2974376T3 (es) 2024-06-27

Similar Documents

Publication Publication Date Title
US11167004B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
KR102955533B1 (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
RU2759630C2 (ru) Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
US20230102151A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
KR20240049351A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
US20230203149A1 (en) Treatment of atopic dermatitis
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
HK40103467A (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
JP6923594B2 (ja) Il−4rアンタゴニストを投与することにより喘息を処置又は予防するための方法
CN117715938A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
HK40010552A (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
HK40010552B (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190419

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200907

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220330

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220929

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220330

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221226

PJ0201 Trial against decision of rejection

Patent event date: 20221226

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20220929

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2022101002354

Request date: 20221226

J301 Trial decision

Free format text: TRIAL NUMBER: 2022101002354; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20221226

Effective date: 20230322

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20230322

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20221226

Decision date: 20230322

Appeal identifier: 2022101002354